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the basis of the unfolded protein response (UPR). Activated in response to the
accumulation of misfolded proteins, the UPR can halt protein translation while
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a conserved three-tier molecular cascade. However, prolonged activation of the UPR
can result in the maladaptation of the system, resulting in the activation of inflammatory
and apoptotic effectors. Recently, UPR and its involvement in neurodegenerative
disease has attracted much interest, and numerous potentially "drugable" points of
crosstalk are now emerging.
Here, we summarise the functions of ER and UPR, and highlight evidence for its
potential role in the pathogenesis of Alzheimer's disease (AD), before discussing
several key targets with therapeutic potential.
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Covering Letter
Reviewer Comments: 
 
Reviewer #1: This submission BP-17-20 describes the intrinsic machinery which helps the cell during 
pathological events to expel abnormally folded proteins. One such proteinopathy is Alzheimer's 
disease, in which multiple proteins are processed and aggregated into clumps which the cell has to 
expel. A further corollary of this processing anomaly is the induction of inflammatory reactions. All 
these mechanisms provide potential targets for disease-modifying treatments of neurodegenerative 
diseases. 
As the answer of the cell to abnormally folded proteins, the UPR provides a protective mechanism 
for the endoplasmic reticulum and aids in the destruction of proteinaceous aggregates. It comprises 
three semi-independent cellular pathways, which the authors have summarised in Fig. 1. Important 
not only in the context of AD is the observation that all proteinopathies are sensitive to UPR as a 
disease-related mechanism. So understanding the mechanist underpinnings for one disease will 
likely be directly translatable to the other. For AD, there is now an established link between UPR and 
amyloid/tau pathology. 
The authors describe in great detail, how the cellular cascades interlink and how crosstalk can be 
established once any single or multiple UPR pathways are activated. Chronic activation of UPR is 
likely a reaction to any stressor which is present continuously. It follows that selective acute 
activation of the UPR is protective to the cell, but long-lasting UPR activity likely ends in apoptosis. 
Therefore, suppression of UPR (and possibly its specific components) provides a novel molecular 
target for disease treatment. Proof of efficacy of PERK or elF2 blockers is provided by lowered 
amyloid levels and reduced tau phosphorylation, and many interactive processes (Calcium 
homeostasis; glutamate toxicity, etc.) are presented. This also includes early evidence for the 
beneficial effects of UPR suppression on cognition and behaviour in general. 
 
While this is a welcome addition to the overall collection of papers on dementia for this issue, there 
are several issues here: 
 
1. The manuscript could be improved in its language and I below list some of the spelling mistakes I 
found. 
 
2. On page 4, abbreviations in paragraph 2: The abbreviation DGP is introduced as diacylglycerol 
phosphate. Later, DGP is combined with other terms which are not related to diacylglycerol and this 
is confusing.  
Response: 
 In order to avoid confusion abbreviations relating to DGP have been removed. 
 
3. Page 8, end of section 2.1.1. It would be quite instructive if some additional work on PERK and JNK 
in the context of memory formation/Learning could be added here. Specifically, I am thinking of the 
work of Zhu S et al., 2016, Plos One; and Ounallah-Saad et al in JNeuroscience. Both papers report 
on the cognitive benefits of a lowering of PERK by either genetic or pharmacological means. 
 
Response to Reviewers
Reply 
We thank the reviewer for drawing our attention to the recent work of Zhu et al. On page 8, we had 
already discussed the findings of Ounallah-Saad et al, but have now modified the paragraph to read 
as follows: 
“Interestingly, despite the superior performance of genetically deficient PERK mice in 
behavioural tasks that require protein synthesis for learning , such mice demonstrated 
reduced working memory in several tasks known to be independent of protein synthesis. 
The latter may indicate an additional role of PERK in the regulation Ca2+ dynamics (Zhu et al., 
2016)”. 
 
4. Section 2.1.3: Recently Zhang Y et al. (Neurosci Res. 41 : 2517- 2016) provided evidence that 
inhibition of ATF-6 can recover deficits in spatial learning in rats. While this is not direct evidence for 
a potentially protective role of suppressing UPR against AD pathology, it provides indirect support 
for a putative treatment against the chronic expression of ATF-6 and I would think this could be 
added to the section. 
Reply 
We have now added a commentary on this interesting finding.  Page 11 now reads: 
“Nevertheless, at least in Parkinson’s disease, the activation of ATF-6 has been shown to be 
protective in association with an increased expression of the ERAD machinery (Egawa et al., 
2011) yet the deposition of α-synuclein may inhibit ATF-6 activation and ER-Golgi trafficking 
(Credle et al., 2015). Despite this protective role, recent work suggests that administration 
of taurine, may protect aged rats from isoflurane-induced hippocampal apoptosis via the 
reduction of CHOP in an ATF-6 dependent manor (Zhang et al., 2016b). These contradictory 
findings, highly the need for increased research into the role of ATF-6 in AD and it’s 
pathology.” 
 
 5. Page 19, second paragraph: FDA approval for Memantine (Namenda) is for moderate-to-severe 
AD, not as stated by the authors for mild-to-moderate AD. Please correct. 
Reply 
This has been amended 
 
 
 
 
6. Page 19, last paragraph: the authors describe the efficiency of 'Dimebon' on mitochondrial 
function. However, Dimebon is the trade name and to be consistent with the previous paragraph, I 
suggest that the authors replace it with the compound name - Latrepirdine. 
Reply 
This has been amended 
 
7. Table 1: The table could be referenced better in the main text as it contains information for 
multiple sections, but is only cited on page 15. 
Reply 
Reference to the table is now provided page 15, 16, 18 and 19 at relevant points. 
 
Please correct: (elements to be added are underlined) 
- Page 3, line of last paragraph (1.2 Protein Folding): it should read … post-translational modification 
….. 
- Page 4, 7 from bottom: delete ultimately 
- Page 5, line 2: should read …one aspect has consequences….. 
- Page 5, line 18, end of line. Delete one …in in … 
- Page 5, last line. End sentence after Ogata et al. 
- Page 6, line 7 should read: … and hence a promising ….. 
- Page 8, line 5 from bottom should read: ….separated by an intronic….. 
- Page 9, line 9: please add to …not only acts as a protein chaperone ….. 
- Page 9, line 11, please delete as indicated: …accordance with the UPR…. 
- Page 9, line 14: it should read …secretases … 
- Page 10, line 2: overserved - not correct 
- Page 10, Line 9: ..variety of growth factor deprivations … - makes no sense. 
- Page 10, line 15 from bottom: …JNK activation, in particular …. been linked with the age-dep….. - 
please add. 
- Page 10, line 10 from bottom: …the association of JNK activation …. - please add. 
- Page 12, line 11: sustained pathological environment - is this correct? 
- Page 12, line 15, end of sentence: … as well as apoptosis. - is this correct (I do not understand). 
- Page 13, line 2: …compromise of ER physiology …. 
- Page 13, line 15 from bottom: …stress led to an similar … - please delete. 
- Page 14, line 9 from bottom: These include … - delete s 
- Page 14, last line: … the outcome for molecular ER stress pathways remains unreported. This 
sentence makes no sense to me. Please reword. 
- Page 15, 7: …in systemic disease models .. - delete s in diseases! 
- Page 15, line 16: … rather than … 
- Page 16, line 10: please correct to .. Tg2576 mice … 
- Page 16, line 13: … but not their maintenance. Makes no sense, please rephrase. 
- Page 16, line 10 from bottom: please correct author name to: Guthrie et al 
- Page 16, line 8 from bottom: … tauopathy models and …. 
- Page 16, line 2 from bottom: … limited the drug's therapeutic … 
- Page 17, line 14: … whilst actually …. 
- Page 18, line 16 from bottom: .. injected with 18ibrillary…. - please correct. 
- Page 19, line 18: excitotoxicity. 
 
Reply 
 These changes have been made and can be found highlighted in the text. 
 
 
Reviewer #2: 
This is an interesting review about the unfolded protein response in AD, and the prospective 
pathways of the unfolded protein response. This all leads to putative therapeutic targets to slow 
down the progression of AD. It is a timely review, and the selected papers (although it is not made 
clear which selection procedure was followed) seem adequate in most cases. The underlying 
mechanisms are well described, with substantial detail. As a consequence, though, the authors do 
not show much mercy to readers less familiar to the many interactions and players in this area. 
Nevertheless just enough concluding sentences and brief summaries are given to keep the review 
readable. In addition, the figure is of great help, nicely depicting the main players and interactions. 
All together this is a nice and valuable review. I have only some minor issues listed below. 
 
1) End page 5: it is a long sentence; better to split it up.  
Reply 
Sentence has now been broken into two to read:  
“In concert, all three arms of UPR also act to promote the expression/activation of pro-inflammatory 
mediators via the transcription factor activating protein-1 (AP-1) and nuclear factor κB (NF-κB;  Garg 
et al., 2012).  Inflammatory cells recruited to the damaged tissues may act as further contributors to 
cellular dysfunction and apoptosis.” 
 
2) Not all abbreviations are introduced in the text (for example BIP), although they are listed in the 
legend of figure 1. Please check carefully. 
 
Reply 
The manuscript has check for these omissions. 
 
3) There are many typo's in the manuscript, like "within in the Chinese population” (p9), "mutation 
have been" (p10), table instead of Table, Berridge 2009 = Berridge 2010, etc etc. Please check 
carefully! 
Reply 
The manuscript has been checked and typos corrected. 
 4) page 18: "AD rats". Please rephrase as these rats do not have AD 
Reply 
“AD rats” has been rephrased to a “rat model of AD” 
 
5) Please explain what ibrillary means (ibrillaryAB1-42), as I assume not all readers will know.  
Reply 
We apologises for the confusion on this point, this is a result of a typo and should read fibrillary, the 
manuscript has been amended accordingly 
 
6) Berridge 2010 is not the correct citation for the calcium hypothesis of AD. Please rephrase 
(reviewed in Berridge 2010) or cite the original papers here. 
Reply 
We have amended this to read “reviewed in Berridge, 2010” 
 
7) A brief statement on how the cited papers were selected (selection criteria) would be 
appreciated. 
In addition to key papers (largely reviews) that introduce the broader topic, we have selected papers 
that offer novel aspects of UPR’s role, either functionally or as drug targets. 
 
 
Figure Click here to download Figure Figure 1.tif 
Drug Mode of action In vitro outcomes In vivo outcomes References 
Endogenous chaperone promoters  
BIX 
Increase in BIP, GRP94 
and calreticulin  
 Chemically induced UPR - Reduced caspase activation 
and apoptotic cell death  
Cerebral artery occlusion and  chemical induced 
retinal damage -Reduced CHOP and XBP-1 
expression and neuronal death.   
Inokuchi et al., 2009 
Kudo et al., 2007 
Oida et al., 2008+2010 
MS275 HDAC Inhibition 
Diminished ERSRE 
repression  
Increased BIP expression 
 
N.R. Baumeister et al., 2009 
Trichostain A 
Valproic acid Increased BIP expression Increased BIP expression in rat cortex Wang et al., 1999 
Proteostasis promoters 
PBA 
Undetermined.  
Likely indirect  
promotion of protein 
chaperone handling 
Aβ treatment -Decreased BIP and CHOP expression, JNK 
activation and p-tau.* 
Tau 35 mice -Decreased p-tau and synaptic loss.                                                                                      
AD mice - Age dependent reduction in plaque load, 
GSK3β activation and p-tau and maintained 
synaptic integrity. Improved cognitive 
performance.  
Bondulich et al., 2016
Cuadrado-Tejedor et al., 2013. 
Ricobaraza et al., 2009+2012 
Wiley et al., 2011 
Zhang et al., 2016 
TUDCA 
Chemically induced UPR -Reduced apoptotic cell death.                                                   
Aβ treatment - Diminished spine loss, pro-apoptotic BAX 
expression, p-tau and JNK and caspase activation. 
Reduced apoptotic cell death.* 
AD  mice -Reduced plaque deposition,  GSK3β 
activation, p-tau, inflammation and maintained 
synaptic integrity . Improved cognitive 
performance. 
Dionísio et al., 2015 
Lo et al., 2013 
Nunes et al., 2012 
Ramalho et al. 
2004+2006+2013 
Sola et al., 2003 
Viana et al., 2010 
JNK inhibitors 
D-JNKI 1  Substrate site  N.R. 
AD mice - Decreased plaque load and Aβ  
oligomers. Improved synaptic plasticity and 
cognitive performance. 
Sclip et al., 2011 
Ginsenoside Rg1 
Gensing extract -
prominent JNK 
inhibition 
N.R. 
AD rat -Decreased BIP, GRP94 and IRE-1 expression 
and caspase activation. Reduced plaque and tau 
load.  
Mu et al., 2015 
SP600125 ATP site  
Aβ treatment- Reduced Bcl-X and Bcl-W pro-apoptotic 
factors and cytokine release and cell death.*                                                                                                
FAD gene expression - Protective against H2O2 challenge    
Aβ treatment- maintained Bcl2 expression and 
mitochondrial biogensis, reduced BAX expression 
and caspase activation.      
AD mice - Decreased plaque load, p-tau and 
inflammation. Improved cognitive performance. 
Bamji-Mirza et al., 2014 
Mahamnadi et al., 2016 
Mahmoudreza et al., 2011 
Marques et al., 2003 
Xu et al., 2015 
Yao et al.,2005 
Yenki et al., 2013 
Zhou et al., 2015 
  
Table
PERK / eIF2α pathway inhibitors 
GSK2606414 PERK inhibitor-ATP site 
Chemically induced UPR - Decreased p-eIF2α and 
release of pro-inflammatory cytokines.                      
2DG Torpor model –Decreased p- eIF2α and p-tau. 
 rTg4510 tau mice - Decreased p-PERK, p- eIF2α, 
ATF-4 expression, GSK3β activation, p-tau and 
neuronal loss. 
Guthrie et al., 2016 
Radford et al., 2015 
Van der Harg et al., 2014 
ISRIB 
Inhibitor of 
downstream eIF2α 
pathways 
Chemically induced UPR- Reduced ATF4, CHOP and 
GADD34 expression, maintained protein synthesis but 
increased apoptosis. 
Prion inoculated mice - Unaltered p-eIF2α, 
reduced ATF4 expression, degeneration, protein 
synthesis recovery and increased survival. 
Halliday et al., 2015 
Sidrauski et al., 2013 
GSK3 Inhibitors 
Lithium Undetermined  
Chemically induced UPR -Increased BIP and anti-
apoptotic Bcl2 expression. Decreased CHOP expression 
and caspase activation and cell death.*  
AD mice – Decreased plaque load, reduced APP full 
length and CTFs and p-APP and p-Tau. Reduced 
astrocyte activation and maintained synaptic 
markers. Improved cognitive performance. 
Avrahami et al., 2013 
Chen et al., 2004 
Hiroi et al., 2005 
Hu et al., 2009 
Meares et al., 2011 
Rockenstein et al., 2007 
Song et al., 2002 
Serenó et al., 2009 
Takadera et al., 2006 
Toledo and Inestrosa, 2010 
Ly et al., 2012 
L803-mts 
Substrate  site  
AD mice – Decreased plaque load.  Improved 
cognitive performance 
TDZD 
Non-ATP site  
AD mice – reduced plaque load, p-tau and gliosis, 
Improved cognitive performance. 
BIO 
ATP site  
Aβ treatment – reduced p-tau, p-JNK, caspase 
activation, gliosis and neurodegeneration.   
AD mice- Reduced Aβ, reduced BACE1 expression, 
reduced NF- κB 
CHIR99021 
Paullone derivatives 
SB216763 
Ca2+ modulators 
Dantrolene RYR antagonist 
Amyloidogenic oligomer treatment - Decreased BIP 
expression and caspase activation.  
Cerebral artery occlusion model -Decreased p- 
PERK and p-eIF2α, and infarct volume.   
AD mouse model - Decreased Aβ production and 
plaque load.  Improved cognitive performance. 
Li et al., 2005     
Oulès et al., 2012 
Teixeira et al., 2006                   
 
Table 1: UPR-targeting pharmacological agents.  Drug categories are listed based on the primary mode of action, and major outcomes reported in vitro and in vivo. 
Phosphorylation is indicated by a “p-“ prefix . Where drugs have been evaluated for protective abilities in disease models / or cellular stress the description is given in bold. * 
denotes where in vitro studies have been conducted in primary neuronal cultures as oppose to cell lines.  Abbreviations: Aβ = beta amyloid, AD= Alzheimer’s disease,  ATF-4 = 
Activating transcription factor 4, ATP= adenosine triphosphate, BACE1= β secretase,  BAX= Bcl2 associated X, Bcl = B-cell lymphoma, BIO= 6-bromoindirubin-3′-oxime, BIP = 
binding immunoglobulin protein, BIX= BIP inducer X, CHOP= CCAAT enhancer binding protein homologous protein, eIF2α = eukaryotic initiation factor 2α kinase, ERSRE= 
endoplasmic reticulum stress response element, GADD34 = growth arrest and DNA damage inducible protein 34, GRP94 = glucose regulated protein 94 , GSK3β, Glycogen 
syntheses kinase 3β, HDAC = histone deacetylates, IRE-1 = inositol-requiring enzyme 1, ISRIB = integrated stress response inhibitor, JNK= Jun-N-Kinase, NF-κB= Nuclear factor κB,  
N.R. = not reported, PBA= 4-phenyl butyric acid, PERK = PRK-like ER kinase , RYR = ryanodine receptor, TDZD= thiadiazolidinone,  TUDCA = tauroursodeoxycholic acid, UPR= 
Unfolded Protein Response, XBP-1 = Xbox protein 1 and 2DG = 2-deoxy-D-glucose. 
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Abstract  
Many vital interdependent cellular functions including proteostasis, lipogenesis and Ca2+ 
homeostasis are executed by the endoplasmic reticulum (ER). Exogenous insults can impair 
ER performance:, this must be rapidly corrected or cell death will ensue. Protective 
adaptations can boost the functional capacity of the ER and forms the basis of the unfolded 
protein response (UPR). Activated in response to the accumulation of misfolded proteins, the 
UPR can halt protein translation while increasing protein-handling chaperones and the 
degradation of erroneous proteins via a conserved three-tier molecular cascade. However, 
prolonged activation of the UPR can result in the maladaptation of the system, resulting in 
the activation of inflammatory and apoptotic effectors. Recently, UPR and its involvement in 
neurodegenerative disease has attracted much interest, and numerous potentially 
“drugable” points of crosstalk are now emerging.  
Here, we summarise the functions of ER and UPR, and highlight evidence for its potential role 
in the pathogenesis of Alzheimer’s disease (AD), before discussing several key targets with 
therapeutic potential.  
Keywords: Amyloid, Alzheimer’s disease, apoptosis, endoplasmic reticulum, ER stress, tau, 
neurodegeneration, homeostasis, proteostasis, drug discovery. 
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1. The endoplasmic reticulum and its role in age-related disease  
The endoplasmic reticulum (ER) is central to an array of cellular processes, including protein 
translation and modification (Schwarz and Blower, 2016), lipogenesis (Fagone and Jackowski 
et al., 2009) and Ca2+ homeostasis (Berridge et al., 2003); the disturbance of such functions is 
implicated in a wide range of disease processes. Here, we briefly summarise aspects of ER 
stress associated with neurodegenerative processes. 
1.1. Ca2+ homeostasis 
The ER (in concert with mitochondria) is the cellular organelle responsible for Ca2+ 
homeostasis, and maintains a high Ca2+ gradient (0.1mM ER lumen vs 10nm cytoplasmic; 
Moore et al., 1975). This gradient is crucial particularly for excitable cells such as neurons, as 
it forms the basis for intra- and inter-cellular communication, and must be maintained despite 
the high associated energy demand. ER stores are regulated by the Sarco/endoplasmic Ca2+ 
ATPase pump (SERCA ATPase),; which scavenges passive Ca2+ leaks and recaptures Ca2+ 
released by inositol triphosphate (IP3) signalling, or via Ca2+ induced Ca2+ release due to 
ryanodine receptor (RyR) stimulation (Berridge et al., 2003).  
Both ionotropic and metabotropic signalling can trigger Ca2+ release from ER stores, which in 
turn causes extracellular Ca2+ influx via the activation of store store-operated Ca2+ channels 
(SOCC:; Koss et al., 2009, & 2013), ensuring refilling of ER stores refilling, strengthening Ca2+ 
dependent signalling as well as activating distinct signalling pathways (Bobe et al., 2011, Zou 
et al., 2011;  and Selvaraj et al., 2012). The importance of Ca2+ homeostasis and excitotoxicity 
in neurodegenerative diseases has been acknowledged for many years; respective reviews on 
the topic have been published previously (see for example Berridge, 2010).  
 
1.2. Protein folding 
The ER is the cellular centre for post-translational modification of newly synthesised proteins 
leading to the adoption of the correct tertiary structure. Those mRNA sequences containing 
an ER recognition sequence encode proteins destined for either membrane integration or 
secretion, and contain a sequence recognition particle (SRP). The SRP-guided translocation 
process feeds polypetides into the ER via a highly conserved heterotrimeric transmembrane 
protein channel translocon complex. Once inside, proteins undergo sequential post-
translational modifications via e.g. N-linked glycosylation, signal peptide cleavage, disulphide 
bond formation, pro-isomerization and oligomerization, each of which prompt, facilitate and 
stabilise proper protein folding. Critical to this process are numerous ER ER-resident protein 
chaperones, including members of the heat shock protein (HSP) family, BIP (binding 
immunoglobulin protein) and GRP94 (glucose regulated protein 94), as well as carbohydrate-
selective chaperones such as cCalnexin and  Ccalreticulin (Schwarz and Blower, 2016). Many 
of these chaperones are multifaceted i.e. they carry out a variety of functions dependent on 
their interaction with adaptor proteins and the hydrolysis of ATP. For example, the protein-
Formatted: Font: Bold, Not Italic
Formatted: Indent: Left:  0.25",  No bullets or numbering
Formatted: Indent: Left:  0.5",  No bullets or numbering
Formatted: Indent: Left:  0.5",  No bullets or numbering
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binding chaperone BIP requires nucleotide exchange factors  such as Sil1 to regulate activity-
dependent substrate binding whilst the association of ER J-domain protein (ERDJ) family 
members assists in localising a variety of different substrates and thus exerts a degree of 
functional control. Such functions include the association of BIP’s association with the 
translocon pore that  recruits emerging polypeptides into the ER lumen, whilst also preventing 
ionic flow mediated by ERDJ1/2. Additionally, the binding of unfolded proteins via ERDJ 3/6 
and ERDJ 4/5 promotes binding of BIP’s binding to misfolded proteins and hence their 
subsequent degradation (Braakman and Hebert, 2013). Only successfully chaperoned 
proteins are correctly presented for enzymatic modification and ultimately available for 
transport to the Golgi apparatus.    
1.3. Lipid biosynthesis 
In concert with its roles in protein translation, the ER is the main site for lipid synthesis. High 
levels of glycerol-3-phosphate, O-aclytransferase and 1-acyl-sn-glycerol-3-phosphate O-
acyltransferase, needed for the production of diacyl-glycerol phosphate, are present in the 
ER, alongside phosphatidic acid phosphatase enzymes which convert diacyl-glycerol 
phosphate  to diacylglycerol, the basis of all phospholipids. As such the ER is the primary site 
for production of most gylcerophospholipids, phosphatidylcholine and 
phosphatidylethanolamine, and also the storage of lipids in the form of triacylglycerol (Fagone 
and Jackowski et al., 2009). In contrast to the self-contained production of 
gylcerophospholipids, the production of ceramide-containing sphingolipids is only initiated in 
the ER, which generates ceramides prior to trafficking to the Golgi apparatus where 
sphingolipid synthesis is completed (Futerman and Riezman, 2005).  
 
1.4.  Cross-talk between ER functions 
 A number of studies have demonstrated a high degree of interdependence of ER functions: 
Many protein chaperones that ensure proper protein folding, such as calrecticulin and 
calnexin, not only bind Ca2+ t, thus regulating both basal ER Ca2+ and releasable Ca2+, but also 
limit SOCC activation (Fasolato et al., 1998). Reciprocally, ER Ca2+ oscillations modulate 
chaperone interactions with target proteins, which enable protein folding (Corbett et al., 
1999,). Similarly, balanced lipogenesis, which requires properly folded enzymes, is essential 
for SERCA ATPase modulation. Moreover, lipogenesis itself is regulated by ER luminal Ca2+ (Fu 
et al, 2011). This complementary balance of ER functionality and  integrity is exemplified by 
the three principle means of inducing ER stress: Tunicamycintunicamycin, an inhibitor of N-
link protein glycosylation (Agouni et al., 2011;  and Bassik and Kampmann, 2011 ), 
Thapisgarginthapisgargin, an irreversible inhibitor of the SERCA ATPase pump which induces 
ER Ca2+ store depletion (Rogers et al., 1995;,  Koss et al., 2009,  + 2013), and palmitic acid, a 
saturated fatty acid that in, which integrates into the ER membrane and causes a stress 
response independent of luminal protein folding (Volmer et al., 2013). 
Formatted: Indent: Left:  0.5",  No bullets or numbering
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The inter-dependence between ER regulatory pathways has wide-ranging implications, as 
modifications or disruptions of one aspect has consequences on others. During aging, 
essential protein chaperones such as calnexin and BIP (Brown and Naidoo,  2012), together 
with SOCC (Vanterpool et al., 2005;  Zhao et al., 2008; Brotto, 2011) and SERCA ATPase activity 
(Toescu and Verkhratsky, 2000; Puzianowska-Kuznicka and Kuznicki, 2009), are 
downregulated, lowering ER Ca2+ levels whilst raising cytoplasmic Ca2+ levels, thus priming the 
aged ER for dysfunction. This predisposition of ER to malfunction may be further exacerbated 
by numerous environmental stresses, such as toxic metals, infections, thermal stress and 
hypoxia (Kitamura, 2013), and shows obvious links between neurodegenerative disease and 
metabolic conditions, such as Type 2 diabetes and obesity (T2D, Chakrabarti et al., 2011).  
2. The Unfolded Protein Response (UPR) 
During impaired ER function, the UPR cascade is activated, initially as a physiological adaptive 
response to ER stress, which is initiated when the demand for protein translation exceeds the 
ER’s protein folding capacity of the ER, and hence is caused either by inefficiencies in the ER 
machinery or by excessive protein demand. Errors within the folding process lead to an 
accumulation of mis/unfolded proteins, resulting in the sequestration of BIP, removing the 
inhibitory influence of the chaperone over key ER resident initiators of UPR, which in turn 
activate the stress response.  
An adaptive UPR promotes cell survival via three convergent pathways (see Figure 1) that lead 
to:  
1) The inhibition of general protein synthesis, promoting only the translation of key stress 
genes, via PKR-like ER kinase (PERK) )-mediated phosphorylation of eukaryotic initiation factor 
2α (eIF2α), and thus selective translation of key transcription factors such as Activating 
Transcription Factor 4 (ATF-4).  
2) Increased expression of ER ER-folding proteins via downstream signalling regulated by 
Activating Transcription Factor 6 (ATF-6) and by inositol-requiring enzyme 1 (IRE1).  
3) Increased protein degradation to remove misfolded proteins, via the up regulation of the 
endoplasmic reticulumER- associated protein degradation (ERAD) machinery, via IRE1.  
 
The ultimate function of acute UPR is to enhance the ER’s capacity of the ER for protein 
folding, i.e. once the production capacity meets demand and misfolded proteins are removed, 
UPR is deactivated and normal proteostasis resumed (Chakrabarti et al., 2011).  However, 
under conditions of chronic cellular stress a sustained UPR activation ultimately results in 
maladaptation and enters a pathological phase. This is signalled via the activation of Jun-N-
Kinase (JNK), downstream of IRE1, and the selective translation of the pro-apoptotic mediator 
CCAAT enhancer binding protein homologous protein (CHOP), promoted by ATF-4 and ATF-6 
(Fig. 1). These secondary UPR mediators converge upon the B-cell lymphoma-2 (Bcl2) protein 
family, hence differentially regulating their activity to induce autophagy and/or apoptosis 
(Bassik et al., 2004; Ogata et al., 2006). The former predicts cell survival by assisting in the 
degradation of misfolded proteins, whilst the latter results in cell death via caspase activation. 
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In concert, all three UPR arms also act to promote the expression/activation of pro-
inflammatory mediators via the transcription factor activating protein-1 (AP-1) and nuclear 
factor κB (NF-κB:;  Garg et al., 2012).  Inflammatory cells recruited to the damaged tissues may 
further contribute to cellular dysfunction and apoptosis.  
Many connections between UPR and traditional AD pathology have recently emerged. This 
has led to the suggestion that it UPR may be a central pathological pathway, and hence offer 
promising therapeutic targets for a range of neurodegenerative diseases (for an overview, see 
Figure 1).  
2.1. UPR and Neurodegeneration 
Neurodegenerative disorders are also classed as ‘proteinopathies’, immediately recognising 
the central relevance of ER- and UPR-related functions. Moreover, the vast majority of 
neurodegenerative cases are idiopathic, which suggest a major impact of age, environment, 
and lifestyle factors. Over the last decade or so, a number of post-mortem investigations have 
identified elevated UPR markers as present in the tissue most severely affected as a result of 
many neurodegenerative diseases, including AD (Hoozemans et al., 2005, 2009), tauopathies 
(Nijholt et al., 2012), Parkinson’s disease (Hoozemans et al., 2007), Lewy body dementia (Baek 
et al., 2016) and amyotrophic lateral sclerosis (ALS:; Atkin et al., 2008; for a recent overview, 
see Scheper and Hoozemans, 2015).  
Specific to AD, investigations have centred on the hippocampus, and demonstrated an 
increase in several key markers of UPR, such as BIP, phosphorylated (p-)PERK, p-IRE and p-
eIF2α (Hoozemans et al., 2005, +  2009; Unterberger et al., 2006). Immunohistological 
investigations frequently report a close association of elevated UPR markers and neurons 
containing pre-tangle phospho-tau pathology. The correlation between the presence of tau 
pathology and ER stress is further corroborated by neuropathological investigations into 
tauopathy cases (Nijholt et al., 2012) and from mixed-dementia cases where tau as well as α-
synuclein may cause an additive burden (Baek et al., 2016). Despite this evidence, there are 
several studies which failed to find conclusive evidence for the induction of UPR across 
affected brain regions. Notably, a decline in total and phosphorylated PERK and eIF2α has 
been detected despite the upregulation of downstream mediators such as ATF-4, CHOP and 
the pro-apoptotic Bcl2 associated X (BAX) protein (de la Monte et al., 2012). Overall, the 
evidence appears weaker in temporal and frontal cortices than the robust detection of these 
UPR mediators in the hippocampus (see de la Monte et al, 2012;, Baek et al., 2016). Critically, 
it must be considered that many negative findings stem from lysed tissues and thus prominent 
activation of signalling cascades restricted to specific neuronal populations may be masked. 
Equally, given that these principle activators of UPR are dependent on protein 
phosphorylation, post-mortem dephosphorylation of substrates must be considered as a 
factor.  
2.1.1. PERK  
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The most widely studied arm of the UPR response is the PERK- eIF2α axis. This key component 
is central to and overlapping with the ‘integrated stress response (ISR)’, which is triggered by 
a wide range of cellular stressors. eIF2α phosphorylation regulates protein translation, cell 
survival and apoptosis via stress-responsive kinases. So far, these kinases comprise PERK, 
protein kinase double-stranded RNA-dependent (PKR), general control non-depressible-2 
(GCN2) and Heme-regulated inhibitor (HRI). All are regulated by dimerization and 
autophosphorylation;, however, signal specificity specificities arise due to each kinase having 
differing sensitivity to varying cellular stressors, differential subcellular locations and 
additional substrates beyond eIF2α. Whilst HRI is restricted to cells of the erythroid cell linage 
and reactive to iron deficiency, PERK, PKR and GCN2 are widely expressed and prominent 
within the CNS. PERK is the principle kinase for eIF2α phosphorylation in response to ER stress, 
yet PKR activation also occurs in response to inflammatory, oxidative and ER stress as well as 
viral infection. Similarly, GCN2 demonstrates overlapping activation stimuli and responds 
towards viral infection, amino-acid and glucose depletion, as well as UV irradiation (Donnelly 
et al., 2013).  
The rate-limiting step in de-novo protein synthesis is translational initiation via presentation 
of Met-tRNAMet by eIF2 complex to the ribosomes. This association of Met-tRNAMET with eIF2 
is regulated by the binding of GTP, which, after hydrolysis to GDP, requires replacement with 
GTP by the nucleotide exchange factor eIF2B. The phosphorylation of eIF2α at Ser51 induced 
by ISR kinases effectively inhibits the association of eIF2B, preventing GTP exchange. Thus, 
the levels of eIF2α bound to GTP required for the presentation of Met-tRNAMET fall, effectively 
preventing ribosomes from initiating translation (reviewed in Donnelly et al., 2013). Even 
though overall translation is heavily reduced as a consequence, translation of mRNA with 
inhibitory upstream open reading frames (ORF) is paradoxically increased, as altered 
ribosomal engagement can bypass this region, promoting their translation. It is by this 
mechanism that ER stress and thus eIF2α phosphorylation can lead to increased expression 
of activating transcription factors such as ATF-4 and consequently CHOP (Vattem and Wek, 
2004 and Palam et al., 2011).  
Of notable relevance for AD is the enhanced expression of ATF-4 and CHOP, but also β-
secretase (BACE1), all derived from mRNA mRNA-containing inhibitory ORFs (Lammich et al., 
2004; Zhou and Song, 2006). As BACE1 is the rate-limiting secretase for the cleavage of 
amyloid precursor protein (APP), several studies have demonstrated that eIF2α 
phosphorylation, induced either by PERK (O’Connor et al., 2008) or PKR (Mouton-Liger et al., 
2012), can ultimately facilitate BACE expression and thus β-amyloid (Aβ) production. Recent 
work suggests a further mechanism of eIF2α phosphorylation to modulate Aβ production, as 
ATF-4 regulates both BACE1 as well as α-secretase / ADAM10 (Reinhardt et al., 2014). 
However, the overall impact of such regulations remains to be fully determined.  
In addition to the modulation of Aβ production, the PERK-eIF2α axis is critically involved in 
the regulation of synaptic plasticity, and thus mechanisms involved in memory formation, 
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likely via direct actions as opposed to actions downstream from amyloid β (Aβ) production. 
Protein translation is required for memory formation, and recent evidence has highlighted 
eIF2α as the limiting factor. Hence, the prolonged phosphorylation of eIF2α could essentially 
deny neurons the de-novo proteins required for structural adaptations such as synaptic 
remodelling, essential for learning and memory. Indeed, wild-type mice treated acutely with 
a p-eIF2α inhibitor (ISRIB, see below for more details) demonstrated enhanced memory 
performance in both hippocampus-dependent and -independent learning tasks (Sidrauski et 
al., 2013), and the transient inhibition of PERK was associated with enhanced cortex-
dependent taste learning (Ounallah-Saad et al., 2014).    Interestingly, despite the superior 
performance of genetically deficient PERK mice in behavioural tasks that require protein 
synthesis for learning, such mice demonstrated reduced working memory in several tasks 
known to be independent of protein synthesis. The latter may indicate an additional role of 
PERK in the regulation Ca2+ dynamics (Zhu et al., 2016). Nevertheless, the regulation of protein 
synthesis dependent memory via p-eIF2α is likely to be multifaceted, as ATF-4 (aka CREB-2) is 
widely accepted to be a repressor of cAMP-responsive element (CREB) )-mediated gene 
expression, required for the conversion of short- to long-term memory (Kida and Serita, 
2014).  Although a variety of consequences for memory and long-term potentiation have been 
observed following inhibition of each of the eIF2α kinases (Trinh and Klann, 2013), Aβ- 
mediated inhibition of LTP in hippocampal slices was dependent on PERK. Conversely, the 
deletion of PERK prevented the elevation of p-eIF2α levels, inhibition of protein translation 
as well asand memory deficits in a variety of behavioural paradigms, in a familial AD (APPswe/ 
PS1ΔE9) mouse model (Ma et al., 2013). Similar results have been observed in 5xFAD mice 
where PERK but not GCN2 haplo-insuffciency blocked the age-dependent increase in BACE1 
expression, alongside memory deficits and cholinergic degeneration (Devi and Ohno, 2013 + 
2014).   
Evidence for the activation of PERK in response to exogenous Aβ is weak, as only aggregated, 
fibrillar Aβ and not oligomeric Aβ increased PERK phosphorylation (Lee et al., 2010). On the 
other hand, accumulation of pathological tau reportedly resulted in PERK activation 
(Abisambra et al., 2013; Radford et al., 2015). Hence, Aβ may act indirectly via tau pathology, 
or alternatively via inflammatory stressors such as Tumour Necrosis Factor α (TNFα), which 
activates PKR and hence the p-eIF2α mediated inhibition of protein translation. This would 
also result in the activation of the additional arms of UPR (Lourenco et al., 2013; Clarke et al., 
2015). 
 
2.1.2 IRE1 
Distinct from the PERK axis of the UPR, IRE1 IRE1-mediated pathways are also closely 
associated with AD pathology. IRE1 is a trans-ER-membrane protein containing both 
endoribonuclease and serine/theronine kinase domains within the cytoplasmic domain 
(Tirasophon et al., 1998). Once unbound from BIP, IRE1 oligomerises and autophosphorylates, 
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which activates IRE1’s the endoribonuclease domain of IRE1 and generates X-box-protein-1 
(XBP-1) mRNA (Yoshida et al., 2001). At rest, XBP-1 mRNA exists in an unspliced form (XBP-
1u), i.e. the DNA-binding domain and the activation domain are separated by an intronic 
sequence. The translation of XBP-1u mRNA results in a protein deficient for gene activation, 
which is rapidly degraded. In contrast, upon activation of IRE1’s nuclease activity, the intronic 
sequence of XBP-1u is excised, inducing a frame shift which allows for full translation of XBP-
1s, a competent transcription factor (Yoshida et al., 2007). 
Although a degree of cell type type-specific gene activation has been reported, approximately 
~95 core genes are upregulated as a result of XBP-1 splicing, these which include ER co-
chaperones for BIP, ERDJ4 as well as P58IPK and modestly BIP itself, but also calrecticulin and 
calnexin, as well as components of ERAD such as ER degradation-enhancing α mannosidase-
like protein, but also core UPR mediators such as PERK, ATF-4 and XBP-1 (Lee et al., 2003; 
Acosta-Alvear et al., 2007).  Together, this profile likely enhances the protein protein-folding 
capacity of the ER and facilitates protein clearance. It may also provide a feedback loop to 
modulate the ongoing UPR by increasing key UPR mediators, but also via the elevation of 
P58IPK w, which not only acts as a protein chaperone but is also associated with the inhibition 
of eIF2α kinases, PERK and PKR (Yan et al., 2002; van Huizen et al., 2003).  
The activation of IRE1 is acutely associated with cell survival, yet during sustained ER stress is 
linked with apoptosis. In addition to classic ER stress stress-related transcription, a number of 
AD-relevant gene transcripts may also be regulated, for example the γ-secretase components 
presenilin 1 (PS1) and Nicastrin nicastrin as well as APP trafficking proteins and the tau kinase 
cyclin dependent kinase 5 (Acosta-Alvear et al., 2007). However, such observations were 
based on the ectopic expression of XBP-1s in muscle and secretory cells. In contrast, 
overexpression of XBP-1 in cells of a neuronal lineage strongly enhanced the expression of 
ADAM10, which was recapitulated following pharmacological induction of UPR (Reinhardt et 
al., 2014). 
Across the spectrum of neurodegenerative conditions, the involvement of XBP-1 appears 
inconsistent. In vitro evidence has suggested strong activation by both α-synuclein and Aβ 
oligomers, yet XBP-1 appears relatively insensitive to other toxic aggregates, e.g. prion 
protein or the familial British dementia amyloid protein (Castillo-Carranza et al., 2012). In 
mouse models of ALS (Hetz et al., 2009) and Huntington’s disease (Vidal et al., 2012), the 
genetic removal of XBP-1  protected against the onset of disease, while increasing XBP-1 
expression appeared protective against Aβ toxicity in cultured neurons (Casas-Tinto et al., 
2011). This protective potential is supported by observations in both the 5xFAD and an 
APP/PS1 AD mouse model, where early, pre-symptomatic upregulation of spliced XPB-1 
coincided with an increased ADAM10 expression, followed by a late stage collapse of XBP-1 
associated with disease progression (Reinhardt et al., 2014). Again, post mortem data report 
either an increase of IRE1 mediated activation of XBP-1 (Lee et al., 2010), or conversely a 
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decrease of spliced XBP-1 mRNA levels despite a prevalence of increased IRE1 activation 
(Reinhardt et al., 2014).  
Together, the data imply that prolonged UPR signalling may lead to XBP-1 downregulation. 
Certainly, downregulation of XBP-1 would mimic the mechanistic consequences of the XBP-
1116C/G  polymorphism, which disrupts the XBP-1 binding motif and results in lower level of 
transcription (Kakiuchi et al., 2003). This has recently been identified as an AD risk gene within 
the Chinese population (Liu et al., 2013). Similarly, a disruption of XBP-1 signalling may also 
affect the cellular pathology of familial AD, where PS1 mutations have been observed to 
downregulate IRE1 signalling (Katayama et al., 1999 and 2001).  
With respect to Aβ-mediated toxicity, the nuclease activity of IRE1 may appear 
neuroprotective. H, however, IRE1 also interacts with numerous additional substrates via its 
kinase domain, including TNF associated factor 2 (TRAF2) leading to the activation of the well-
established stress activated JUN N-terminal kinase, JNK (Urano et al., 2000). Additional 
connections between IRE1 and JNK comprise numerous cellular stimuli capable of JNK 
activation, including inflammatory signalling via TNFα and interleukin-1 (IL-1), oxidative 
stress, UV irradiation and growth factor deprivations (Cui et al., 2007). Various stimuli engage 
mitogen activated kinase kinase kinases (MAPKKK) which in turn targets MAPK kinases, 
specifically MAKK4 and MAKK7, ultimately phosphorylating JNK. This induces nuclear 
responses (including the canonical c-Jun substrate and nuclear hormone receptors) as well as 
several cytoplasmic changes in ubiquitination-mediated protein degradation, insulin receptor 
substrate 1 and Bcl2 proteins (Bogoyevitch and Kobe, 2006) and pro-inflammatory AP-1 (Garg 
et al., 2012, see below). JNK signalling undoubtedly plays important physiological roles, e.g. 
in brain development, synaptic plasticity and neuronal regeneration, but prolonged activation 
of JNK is prominently associated with apoptosis (Mehan et al., 2011). 
In addition, JNK is capable of phosphorylating tau (Reynolds et al., 1997; Anderton et al., 
2001), but also targets a number of substrates relevant for the Aβ cascade. Upstream from 
the Aβ, APP is an effective substrate of JNK and its phosphorylation at Thr668 effectively 
promotes amyloidogenic cleavage (Standen et al., 2001, and Sclip et al., 2011), potentially via 
modulation of intracellular APP trafficking (Triaca et al., 2016). Downstream signalling links 
JNK with apoptotic pathways, likely via the modulation of apoptotic Bcl2 proteins (Troy et al., 
2001). Consequently, elevated JNK activation, in particular of the p54 forms, has been linked 
with the age-dependent production of Aβ in murine APP/PS1 (Shoji et al., 2000; Savage et al., 
2002), but also in FTD models (Allen et al., 2002). As oligomeric Aβ may trigger tau hyper-
phosphorylation in a JNK dependent manner (Ma et al., 2009; Zhang et al., 2016aa), JNK 
emerges as a potential link and common denominator for stress responses activated by both 
Aβ and tau pathologies. Post-mortem studies further support the this association,   of with 
progression of tau pathology in human AD, i.e. high cytoplasmic levels are found in 
neurofibrillary tangle-s  bearing neurons, but also in a substantial number of tau-positive 
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neurons without mature aggregates (Pei et al., 2001; Lagalwar et al., 2006). Corresponding 
findings have also been observed in cases of human FTD (Lagalwar et al., 2007). 
Recently, IRE1 has also been linked to the activation of another principle tau kinase, glycogen 
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activation of GSK3β by IRE1 has been observed, alongside changes in pro-inflammatory 
cytokines, IL-1 and XBP-1 splicing, leading to a reduction in TNFα (Kim et al., 2015). In neuronal 
cell lines a similar increase in GSK3 activity has also been reported following pharmacological 
UPR induction, yet this shift in activation was attributed to the selective degradation of 
inhibited GSK3 as opposed to enhanced tyrosine phosphorylation, in accordance with post-
mortem investigation (Nijholt et al., 2013).  
GSK3β has demonstrated a striking efficiency in phosphorylating tau and a close association 
with AD pathology (Maqbool et al., 2016). Contributions specifically linked with UPR were 
identified in neuronal cell lines and primary hippocampal neurons (but not fibroblasts or 
astrocytes), where GSK3 activation appeared to contribute to UPR UPR-induced apoptosis, 
either by caspase-3 activation induced by CHOP (Meares et al., 2011) and/or the regulation 
of key ER ER-resident proteins, γ-taxilin and α nascent polypeptide-associated complex 
subunit, two proteins which are downregulated in AD (Hotokezaka et al., 2015). In an APP/PS1 
mouse model, GSK3β activation appeared to facilitate UPR UPR-mediated cell death following 
a series of sub-threshold hypoxic events, as well as exacerbating tau phosphorylation (Wang 
et al., 2013).    
Therefore, both JNK and GSK3β provide mechanistic links between key AD pathologies and 
UPR.  
2.1.3. ATF-6 
The third arm of UPR involves ATF-6, an ER ER-resident transmembrane protein. It is inactive 
in the BIP-bound form, but following the loss of BIP association is trafficked to the Golgi 
apparatus, where proteolysis (via site 1 and 2 proteases) activates the protein and enables 
nuclear transcription of key ER proteins, including chaperones (e.g. BIP, GRP94 and 
Calreticulin) and ERAD components (Shen et al., 2002). ATF-6 also regulates enzymes for 
disulphide-bond formation related to the Ca2+ homeostasis, including SERCA2 gene (Okada et 
al., 2002).  Notability, there is some functional redundancy with XBP-1 in relation to BIP and 
other protein chaperones and ERAD proteins (Lee et al., 2003, Yamamoto et al., 2004), but 
also with ATF-4 in relation to the expression of CHOP (Okada et al., 2002). The ATF-6 pathway 
is arguably the least investigated in relation to neurodegeneration, with few studies 
conducted to establish its role in human diseases or engagement of pathological cascades. 
Nevertheless, at least in Parkinson’s disease, the activation of ATF-6 has been shown to be 
protective, in association with an increased expression of the ERAD machinery (Egawa et al., 
2011) yet the deposition of α-synuclein may inhibit ATF-6 activation and ER-Golgi trafficking 
(Credle et al., 2015). Despite this protective role, recent work suggests that administration of 
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taurine, may protect aged rats from isoflurane-induced hippocampal apoptosis via the 
reduction of CHOP in an ATF-6 dependent manor (Zhang et al., 2016bb). These contradictory 
findings, highlightly the need for increased research into the role of ATF-6 in AD and it’s 
pathology. 
 
 
3. Secondary AD pathologies 
 
Beyond the primary AD pathologies and their implications for neuronal plasticity, UPR likely 
plays an additional role in other degenerative processes. ER stress is closely associated with 
autophagy, inflammation and Ca2+ dyshomeostasis, each of which is implicated in the 
exacerbation of AD. 
 
3.1 UPR & Autophagy  
Macroautophagy is heavily implicated in the clearance of toxic protein species, including tau 
and Aβ (Kim et al., 2011; Salminen et al., 2013), yet in AD, key autophagic proteins such as 
Beclin-1 are progressively reduced, sequestered or cleaved, which correlates with cognitive 
decline (Pickford et al., 2008, Jaeger et al., 2010; Ma et al., 2010). Despite the protective role 
of autophagy as an outcome of UPR, deregulated autophagic processes in AD may facilitate 
disease progression and favour apoptosis. Outcomes are dependent on the balance, 
expression and activity of key Bcl2 proteins, controlled by CHOP (Galehdar et al., 2010) and 
JNK phosphorylation (Bassik et al. 2004), respectively, which modulate autophagy via 
interactions with Beclin-1 (Pattingre et al., 2005, Maiuri et al., 2007; Luo et al., 2012).  
3.2. UPR & Inflammation 
Neuroinflammation is mediated by multi-protein inflammasomes against exogenous 
pathogens and metabolic by-products and involves pro-inflammatory caspases which activate 
cytokines (e.g. IL-1β, IL-18, and IL-33). At present, the nucleotide-binding oligomerization 
domain-like receptor family, pyrin domain-containing-3 (NLRP3) is the best characterized 
inflammasome in AD (Pennisi et al., 2016). Cytokine- and chemokine-expressing microglia 
surround Aβ plaques; and overall levels of these pro-inflammatory agents are elevated in AD 
brain tissue (Akiyama et al., 2000). The recruitment of activated glia via pro-inflammatory 
agents is regulated by AP-1 and NF-κB (Glass et al., 2010). Of interest here is that PERK and 
IRE1 converge to promote the activation of these transcription factors: PERK via the eIF2α- 
mediated downregulation of the NK-κB inhibitor IκB (Jiang et al., 2003) and IRE1 via the 
promotion of IκB degradation and activation of AP-1 via JNK phosphorylation (Hu et al., 2006; 
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Kaneko et al., 2003). Thus, UPR activation has the potential to exacerbate pro-inflammatory 
signalling and ultimately immune-driven cellular damage and neuronal death.  
 
 
3.3 UPR, Ca2+ homeostasis and mitochondrial function 
Cellular dysfunctions and impaired homeostatic UPR has wide-ranging consequences on 
protein translation, but also affects other aspects of cellular physiology such as Ca2+ 
homeostasis and mitochondrial ATP production. UPR UPR-mediated adaptations have a clear 
potential to compromise ER physiology and Ca2+ homeostasis, for example via altered IP3 
receptor activation (Nutt et al., 2002), Ca2+ binding protein chaperones, such as calreticulin, 
and  as well as regulatory enzymes, including various kinases and phosphatases such as PTP1B 
(Agouni et al., 2011), which we have identified as a key regulator of SOCC (Koss et al., 2013). 
Consequently, altered Ca2+ buffering can increase ER luminal Ca2+ uptake, facilitate agonist-
mediated Ca2+ release, affect ER-mitochondria tethering and Ca2+ exchange, and suppress 
SOCC. These changes are key hallmarks of excitotoxicity and lead to enhanced tau 
phosphorylation, as reported for example after experimental depletion of ER Ca2+ stores 
(Hartigan and Johnson., 1999). ER stress-induced Ca2+ dysregulation, as well as changes in Bcl2 
proteins (Adams and Cory, 1998) can disrupt mitochondrial activity, leading to the collapse of 
ATP production and apoptotic processes (Vannuvel et al., 2013). Recently, “mitochondrial 
association membranes” (MAM) have emerged as substrates for ER-mitochondria 
interactions. MAM are specialised areas for lipid metabolism and Ca2+ transfer (Paillusson et 
al., 2016) but also for Aβ production (Schreiner et al., 2015). Interestingly, several key ER 
chaperones, including BIP, calreticulin and calnexin are enriched in MAM (Hayashi et al., 
2009). MAMs are reportedly decreased in ALS, Parkinson’s disease, and as well as TDP-43 
variants of fronto-temporal dementia (Paillusson et al., 2016), but evidence from post-
mortem studies as well as rodent AD models suggest an actual increase in ER-mitochondria 
associations (Hedskog et al., 2013). Similar findings have been reported in fibroblasts isolated 
from both sporadic and familial AD cases (Area-Gomez et al., 2012), and nanomolar Aβ 
concentrations also appeared to promote ER-mitochondria associations as well as Ca2+ 
transfer in neuronal cultures (Hedskog et al., 2013). Additionally, chemically induced ER stress 
led to similar changes, but these were followed by a collapse of ATP production and apoptotic 
activation followed (Bravo et al., 2011; Vannuvel et al., 2013). Clearly, these studies imply that 
mitochondrial pathology and disrupted Ca2+ handling lay lie downstream of the UPR.   
4. Emerging therapeutic targets  
The cellular cascades engaged by UPR activation offer numerous molecular sites and 
pathways for pharmacological intervention. However, the diverse signalling components 
involved and their upstream / downstream pathways paint a complex picture that presents 
challenges, as a complete mechanistic understanding is at present missing.  
Formatted: Indent: Left:  0.25",  No bullets or numbering
Formatted: Font: Bold
Formatted: Indent: Left:  0.25",  No bullets or numbering
14 
  
4.1. Chaperones  
A key concern when therapeutically targeting UPR components is that the ER stress response 
is, at least acutely, protective and essential for normal cellular physiology, and therefore 
caution must be taken when targeting this cascade. One potential strategy is to promote 
chaperones in support of the capacity of the ER’s capacity for protein handling (proteostasis) 
and prevent the induction of chronic UPR, instead of attempting selective downstream 
inhibition.  
In line with this strategy several avenues have been explored in models of neurodegeneration 
(see Table 1). However, many compounds exert a range of cellular actions, which makes 
interpretation of data difficult. Of note, a recent review suggests that a clearer distinction 
should be made between genuine endogenous chaperons (such as HSPs)  and other chemical 
chaperones and ‘proteostasis promoters’, as the actions of the latter compounds are likely 
indirect (Vega et al., 2016).  
4.1.1. ER chaperones 
Drugs promoting the expression of ER ER-specific HSP chaperones may offer a mode of 
intervention, but limited candidate molecules are available at present. To date, only one such 
drug has been identified, i.e. BIP inducer X (BIX), identified via a high throughput BIP reporter 
assay. BIX (1-(-3,4-dihyrdoxy-phenyl)-2-thiocyanate-ethanone) induces a transient increase in 
BIP expression at low micromolar concentrations, as well as modest increases in GRP94, 
calreticulin, but and also CHOP (Kudo et al., 2008). The induction of these ER stress 
components is observed in the absence of PERK or IRE1 activation, yet appears dependent on 
ATF-6 signalling. It protects against chemically induced ER stress and resultant apoptosis, as 
well as the cerebral infarcts, where notably an overall decrease in CHOP expression was 
observed (Kudo et al., 2008; Oida et al., 2008). These results have been largely confirmed in 
response to NMDA and Tunicamycin tunicamycin-induced retinal damage (Inokuchi et al., 
2009).  Although in vivo data indicate a narrow therapeutic window in relation to vessel 
occlusion occlusion-induced cerebral infarct (effective at 3hr but not 6hr post insult:; Oida et 
al., 2010), such limitations may not be of concern when dealing with a progressive 
neurodegenerative disorder. There are at present no reports on the potential of BIX ’s 
potential to perturb the neuropathology or cognitive decline associated with dementia, 
although the genetic overexpression of BIP has proven protective in models of Parkinson’s 
disease (Gorbatyuk et al., 2012).  
Several other compounds show potential to induce increased BIP expression, which appears 
linked to the inhibition of histone deacetylates (HDAC). These include the pan-HDAC inhibitor 
Trichostatin trichostatin A and the class I I-specific HDAC inhibitor MS275 (Baumeister et al., 
2009), but also the mood-stabilising drug valproic acid, which also promotes BIP expression 
dependent on HDAC inhibition (Wang et al., 1999; Shi et al., 2007). Mechanistically, these 
drugs appear to inhibit the endogenous repression of HDAC upon the ER stress response 
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element (ERSRE), in turn promoting BIP expression. Although numerous HDAC inhibitors have 
been tested in AD models in vivo, and beneficial outcomes reported, i.e. successful 
modification of neuropathology and preservation of cognition (Yang et al., 2014; Bang et al., 
2015; Klein et al., 2015), the modulation of ER stress pathways in these models remains to be 
determined. 
 
 
4.1.2. Proteostasis promoters  
Two well-described compounds in this category are tauroursodeoxycholic acid (TUDCA), a 
taurinated form of the endogenous bile acid ursodeoxycholic acid (UDCA), and 4-phenyl 
butyric acid (PBA). These have long been part of health supplements and traditional 
medicines, and are currently used for e.g. liver and muscle support, or urea cycle disorders, 
respectively. They are well established protectants against excess UPR, either when induced 
pharmacologically (Malo et al., 2010; +  2013) or in systemic disease models, such as T2D 
(Ӧzcan et al., 2006).  
Although commonly referred to as chemical chaperones, it remains unclear if these two 
principle compounds behave as such. TUDCA has demonstrated only limited inhibition of 
protein aggregation. It acted primarily indirectly to enhance the properties of endogenous 
chaperones, e.g. by facilitating anti-aggregate capabilities of α-crystallin in retinal lens 
extracts (Song et al., 2011). Equally, TUDCA failed to alter the aggregation of synthetic Aβ1-42, 
despite inhibiting apoptosis induced by similar Aβ application to endothelial cells (Viana et al., 
2009). Given the nature of aggregation assays, these findings are in line with the potential of 
TUDCA to moderate endogenous protein handling rather that direct interaction with the 
aggregating proteins, though the exact mechanisms remain to be determined. Somewhat 
more robustly, PBA directly inhibits aggregation when tested against α-lactalbumin and 
bovine serum albumin (Kubota et al., 2006). However, lacking evidence for its ability to inhibit 
Aβ or indeed tau aggregation, it remains plausible that PBA may regulate AD AD-relevant 
protein aggregation, or indeed more generally AD pathology more generally, by other means 
(see below).  
Despite this uncertainty, both TUDCA and PBA have been well established as neuroprotective 
agents against synthetic Aβ and in APP/PS1 PS1-expressing cell lines and primary cultures 
(Ramalho et al., 2006; Dionisio et al., 2015;  and Zhang et al., 2016a6a). Although most studies 
have not specifically investigated alterations in the ER stress machinery, neuroprotection can 
rather consistently be attributed to the blocking of mitochondria-dependent apoptotic 
pathways via Bcl2 proteins, the reduction of several caspases and the inhibition of JNK 
signalling cascades, at least when tested in vitro (for examples and details, see Table 1).  This 
is consistent with the involvement of mitochondria in Aβ-induced apoptosis and the recent 
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finding that PBA reduces the expression of CHOP and BIP, as well as tau phosphorylation 
following Aβ oligomer treatment of PC12 and primary neuronal cultures (Zhang et al., 2016aa). 
In accordance with the in vitro work, several groups have identified an effective reduction in 
Aβ load, restoration of cognitive function and a preservation of neuronal integrity in AD 
mouse models following various treatment regimes with TUDCA or PBA (see Table 1). Best 
outcomes were often achieved following pre-symptomatic treatment. Long-term treatments 
commonly perturbed Aβ plaque deposition, reduced GSK3β activation along with tau 
phosphorylation, and increased glutamatergic receptor subunit expression as well as 
maintained maintaining synaptic integrity (Wiley et al., 2011; Ricobaraza et al., 2012). Similar 
findings have recently also been reported in an FTD model that expresses an aggregate-prone 
tau fragment (Bondulich et al., 2016). In many studies, the amelioration of AD-relevant 
neuropathology occurred alongside improvements in cognition. Shorter treatments given 
post-symptomatically also improved cognition and reduced tau phosphorylation, while Aβ 
profiles were inconsistent. An effective decrease of cortical Aβ plaques following a 6 months 
TUDCA treatment of APP/PS1 mice was reported when given prior to plaque deposition 
(Nunes et al., 2012; Lo et al., 2013) yet when given following frontal plaque formation failed 
to diminish the load and only reduced the late-stage hippocampal plaque pathology (Dionísio 
et al., 2015). Similarly, treatment of aged Tg2576 mice with PBA did not reduce plaque load 
and even Aβ production, yet cognition and synaptic integrity improved alongside a decreased 
tau phosphorylation (Ricobaraza et al., 2009).  
Therefore, proteostasis promoters may fail to aid plaque clearance and only prevent plaque 
formation. This is also supported by the reduced neuronal loss observed in hAPPWT 
overexpressing mice in the absence of plaques and Aβ over-production (Cuadrado-Tejedor et 
al., 2013), which is indicative of alternative mechanisms of action such as the noted HDAC 
inhibition activity (Kubota et al., 2006). However, comparative studies with PBA and other 
HDAC inhibitors that do not affect the ER’s chaperone system have demonstrated PBA’s 
selective effects of PBA, both for ER-stress induced neuronal toxicity in vitro (Mimori et al., 
2013) and in AD models (Cuadrado-Tejedor et al., 2013).  
4.2. PERK & eIF2α inhibitors 
Despite the evidence provided by genetic manipulation of PERK or its immediate downstream 
substrate eIF2α in models of AD, there are surprisingly few studies utilising pharmacological 
inhibitors of PERK (See Table 1). Two such compounds are GSK2606414 (Axten et al., 2012) 
and the inhibitor of the downstream targets of eIF2α, the so called ‘integrated stress response 
inhibitor’ ISRIB (Sidrauski et al., 2013).  In vitro, GSK2606414 was effective at inhibiting UPR- 
mediated tau phosphorylation in SH-SY5Y cells (Van der Harg et al., 2014) and has 
demonstrated a dose-dependent inhibition of  p-eIF2α activation without altered CHOP or 
ATF-4 levels in isolated astrocytes, leading to a decrease in the expression of pro-
inflammatory cytokines (Guthrie et al., 2016). Currently, there are no reports of this 
neuroprotective potential of GSK2606414 following either AD gene expression or Aβ 
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challenge.  GSK2606414 has only been tested in prion and tauopathy models and although a 
promising reduction of neuronal loss, decreased tau phosphorylation and GSK3β expression 
was were reported, cognitive performance was not assessed (Radford et al., 2015). Upon its 
initial use in vivo, GSK2606414 showed impressive neuroprotective properties, drastically 
reducing any neurodegeneration in response to prion protein inoculation and substantially 
reducing attrition rates. However, systemic inhibition of PERK caused pancreatic toxicity, 
leading to weight loss and high attrition rates, which has severely limited the drug’s 
therapeutic potential (Moreno et al., 2013). More recently, a follow up study using ISRIB, 
which appears devoid of pancreatic toxicity, achieved similar degrees of neuroprotection 
against prion protein inoculation. ISRIB reportedly acts via an as yet unresolved mechanism 
that inhibits downstream signalling of eIF2α, partially restoring protein translation without 
altering eIF2α phosphorylation levels (Halliday et al., 2015). Although examination of 
pancreatic tissue has demonstrated no signs of toxicity or tissue loss, significant weight loss 
was still apparent, the cause of which remains to be determined.  Currently, no reports have 
emerged on the use of ISRIB within AD or FTD models. 
  
4.3. IRE1 modulators 
Few small molecule modulators of IRE1 have been developed thus far. The best characterised 
is 4-methylumbelliferone 8-carbaldehyde (4µ8C), which targets and inhibits the 
endoribonuclease function of IRE1 (Cross et al., 2012), in a similar manner to STF-083010 
(Papandreou et al., 2011);, hence, such drugs fail to address the  potentially diminished XBP-
1 splicing in AD. Equally, several other compounds identified as IRE1α modulators block XBP-
1 splicing whilst actually increasing IRE1 kinase activation and thus autophosphorylation 
(Volkmann et al., 2011). Thus, the dual functional domains of IRE1 in AD and the apparently 
divergent kinase activation (increased) and endoribonuclease function (reduced) means that 
pharmacological targeting of this enzyme is at present problematic. 
Despite these issues, some progress towards pharmacological manipulations specific for one 
functional domain of IRE1 have been made. A comparative study of novel compounds related 
to PBA (see above) has demonstrated potent inhibition of both kinase and endoribonuclease 
functions of IRE1 and as well as the ATF-6 pathway, which may be independent from HDAC 
(Zhang et al., 2013). However, further structural refinement may be needed to offer specific 
inhibition of the IRE1’s kinase function of IRE1, as some analogues favoured the inhibition of 
JNK over XBP-1 splicing (Zhang et al., 2013). Indeed, genetic manipulation of the IRE1 kinase 
domain can produce a kinase-dead IRE1 variant, which still maintained intact RNase 
functionality (Rubio et al, 2011). This work essentially demonstrated that the two functional 
domains can operate in isolation, and thus the selective targeting of each is theoretically 
possibly. Targeting the RNase domain whilst inhibiting / blocking the kinase activity may be 
possible, although no such reports exist for mammalian cells (Korennykh et al., 2009; 
Wiseman et al., 2010). Also, the activation of the IRE1 kinase domain may be required for UPR 
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deactivation;, therefore, kinase-dead IRE1 variants may be more vulnerable to ER stress.  
Nevertheless, several small molecule activators of IRE1 RNase activity have now been 
developed, but cell toxicity remains an issue (Mendez et al., 2015). Interestingly, a significant 
reduction in toxicity could be achieved by co-administration of the PERK inhibitor 
GSK2606414. 
Ultimately, the complexity of targeting IRE1 directly suggests that selective inhibition of 
downstream effector kinases involved in the propagation of the apoptotic cascade may be a 
more promising approach to interrupt chronic UPR and establish protection. 
 
4.4 JNK 
In comparison to many of the other UPR UPR=related targets, there have been more thorough 
investigations into the development of effective JNK inhibitors and characterisation of the 
resulting neuroprotective outcomes in multiple models of AD and other neurodegenerative 
disease (see Table 1). An excellent review has recently been published covering the subject 
extensively (Yarza et al., 2016). Here, particular attention will be given to the direct ATP-
competitive inhibitor SP600125, which has been investigated in relation to UPR and AD 
neurodegeneration. 
SP600125 has relatively high specificity for JNK1-3 over other related kinases (Han et al., 
2001). A number of studies have demonstrated substantial neuroprotection with SP600125 
towards Aβ mediated apoptosis in vitro (Yao et al., 2005; Bamji-Mirza et al., 2014; Xu et al., 
2015). SP600125 when given prior to or in combination with oligomeric Aβ mediated a 
number of UPR relevant signalling pathways, such as the inhibition of Aβ mediated 
suppression of anti-apoptotic Bcl2 proteins Bcl-XI and Bcl-W (Yao et al., 2005) as well as the 
prevention of a key downstream apoptotic effector of CHOP, GADD43 (Xu et al., 2015). Similar 
protective effects have been observed in vivo following acute application of SP600125, e.g. in 
rats intra-hippocampally injected with fibrillary Aβ1-42 (Ramin et al., 2011; Yenki et al., 2013; 
Mahammadi et al., 2016). These studies report preservation of cognitive abilities alongside a 
lower pro-apoptotic expression ratio between Bcl2 and BAX, decreased caspase expression 
and reduction of autophagic markers. Unfortunately, no direct quantification of the principale 
activators of UPR, nor its modulation by JNK inhibition, was reported. Similarly, promising 
effects have been described following chronic SP600125 treatment or the application of  the 
D-JNKI1 JNKI1-inhibiting peptide in AD mouse models, but a direct investigation of UPR 
aspects remain unexplored (Sclip et al., 2011; Zhou et al,. 2015). However, the treatment of 
a rat model of AD with the ginsenoside Rg1, an extract known to inhibit JNK (Zhang et al., 
2015), led to reduced AD pathology and apoptosis via the down-regulation of IRE1 (Mu et al., 
2015).    
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4.5 Other ER / UPR relevant therapeutics: GSK3 inhibitors & Ca2+ stabilisers 
The central role of GSK3 in tau phosphorylation and Aβ production and its involvement in 
both sporadic and familial cases originally led to the GSK3 hypothesis of AD (Hooper et al., 
2008). A range of inhibitors (natural, inorganic metal ions, organo-synthetic, and peptide-like) 
are available and have been probed in models of AD (reviewed in: King et al., 2015, see Table 
1). Lithium is arguably the best-studied inhibitor, and despite its questionable specificity, was 
recently acknowledged as offering dementia protection in adults treated for bipolar disorders 
(Gerhard et al., 2015). Indeed, lithium, but also the synthetic inhibitors, alsteropaullone, 1-
azakenpaullone, SB216763 and TDZD-8 as well as the GSK3-specific inhibitor peptide L803-
mts, inhibits ER stress stress-mediated apoptosis in several neuronal models of 
neurodegeneration (Song et al., 2002; Chen et al., 2004; Hiroi et al., 2005; Takadera et al., 
2006). Mechanistically, the protective effect of GSK3β inhibition would appear to be 
downstream of UPR induction, reducing CHOP expression independent of ATF-4, and leading 
to a reduction in caspase 3 activation and subsequent apoptosis (Meares et al., 2011). 
Notably, the inhibition of GSK3β, may also promote neuronal survival via the increased 
expression of anti-apoptotic Bcl2 proteins and BIP (Hiroi et al., 2005). Despite promising 
protective outcomes in vitro and in an in vivo model of acute liver failure (Chen et al., 2012), 
the exploitation of GSK3β inhibitors for the repression of ER stress in AD models remains to 
be fully investigated. 
A Ca2+ hypothesis of AD has also been proposed (reviewed in Berridge, 2010), and as outlined 
before, identifies the crucial role of ER function, mitochondria and UPR for neuronal 
physiology and homeostatic control. A range of Ca2+ channel blockers specifically targeting 
various Ca2+ permeable channels, including L, P/N type voltage gated channels and the NMDA 
receptor have been trialled against neurodegeneration-related excitotoxicity (Nimmrich and 
Eckert, 2012). Of note, memantine, currently prescribed for AD patients at moderate to 
severe stages, has been marketed based on its NMDA antagonistic actions and the suggested 
prevention of Ca2+ overload, though it should be noted that its cholinergic properties are likely 
more crucial to its temporary benefits (Drever et al, 2007). Nevertheless, further meta-
analysis has demonstrated beneficial outcomes following the treatment of AD sufferers with 
the L-type Ca2+ blocker nimodipine (López-Arrieta and Birks, 2002). In comparison, less work 
has been conducted evaluating drugs targeting ER Ca2+ release mechanisms via IP3 receptors 
and RyR, which may more directly target ER Ca2+ homeostasis and impact on ER stress.  
Interestingly, the RyR antagonist dantrolene reduced neuronal cell death associated with UPR 
activation in a model of cerebral artery occlusion (Li et al., 2005) and inhibited UPR induction 
and subsequent cell death in a model of a rare peripheral amyloidosis (Teixeira et al., 2006). 
Similarly, dantrolene reduced Aβ levels, deficits in synaptic plasticity and memory 
impairments in several AD models (Oulès et al., 2012; Chakroborty et al., 2012; Wu et al., 
2015), although varying protective mechanisms were proposed (Del Prete et al., 2014).   
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Crucially, changes in energy metabolism and impaired glucose handling due to failing 
mitochondria are central to ageing, the primary risk factor for all dementias (Bhatti et al., 
2016). Latrepirdine (tradename: dimebon), an anti-histamine repurposed for treatment of AD 
and Huntington’s disease, showed promise in experimental models and early trials largely 
linked with mitochondrial actions but later failed in phase III clinical trials (Bezprozyanny, 
2010). Other attempts to target mitochondria directly are now under way. For example, 
natural polyphenols such as resveratrol, an anti-oxidant and anti-inflammatory agent found 
in grapes and berries, potentially offers some neuroprotection (Ahmed et al., 2016), while 
other inhibitors of mitochondrial fission are also being developed (Reddy, 2014), but 
implications for UPR pathways remain to be confirmed. 
 
 
5. Conclusions 
Complex signalling pathways related to neuronal homeostasis and proteostasis are currently 
being unravelled and provide a better understanding of cellular physiology and pathology. 
Regulatory mechanisms link UPR not only with protein handling, but also with Ca2+ 
homeostasis and mitochondrial function, metabolics, inflammation, autophagy and synaptic 
plasticity, and a number of promising therapeutic targets are now emerging. However, 
comprehensive investigations into these targets are still required and it is essential to identify 
not just opportunities but also potential pitfalls, so as to avoid failures of future clinical trials. 
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Figure 1: Molecular pathways of UPR and potential mechanisms of cellular damage 
promoting AD-relevant pathology. Damaging factors such as age, environment and lifestyle 
() affect cellular organelles and hence ER protein folding and cellular homeostasis. 
Impairments result in increased misfolded proteins, which accumulate in the ER lumen. These 
sequester protein chaperones such as BIP, and lead to the activation of three UPR-arms via 
PERK, IRE1 and ATF-6. The initially adaptive phase of UPR requires phosphorylation of eIF2α, 
halting general protein translation, whilst favouring the translation of protective stress 
proteins. In parallel, IRE1 activates XBP-1 alongside the cleavage and activation of ATF-6, 
which together promotes the expression of key ER protein chaperones and enhance the ER 
protein degrading machinery (ERAD) to clear misfolded proteins. If this adaptive response can 
restore ER functionality the stress response is terminated. However, if the ER’s protein -
handling capacity of the ER remains impaired and UPR persists, it enters a pathological phase: 
the prolonged blockade of protein translation prevents structural changes essential for 
plasticity:, it increases amyloidogenic processing via BACE1 and PS1, alongside APP trafficking 
proteins as well as the induction of the pro-apoptotic mediator CHOP, which in turn increases 
expression of pro-apoptotic Bcl2 proteins. Supported by the activation of JNK stress kinase 
and GSK3, Bcl2 proteins cause mitochondrial damage as well as autophagy. In conjunction 
with elevated levels of JNK as well as GSK3, IRE1-mediated degradation of anti-inflammatory 
factors leads to the upregulation of AP-1/NFƙB, promoting the production of chemokines and 
cytokines and hence inflammation. The continued alteration of Ca2+-binding chaperones 
impairs Ca2+ homeostasis, this promotes tau phosphorylation and further impairs binding of 
newly translated proteins. *= Kinases activated downstream from IRE kinase domain. For 
abbreviations, see text. 
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Table 1: UPR-targeting pharmacological agents.  Drug categories are listed based on the 
primary mode of action, and major outcomes reported in vitro and in vivo. Phosphorylation 
is indicated by a “p-“ prefix . Where drugs have been evaluated for protective abilities in 
disease models / or cellular stress the description is given in bold. * denotes where in vitro 
studies have been conducted in primary neuronal cultures as oppose to cell lines.  
Abbreviations: Aβ = beta amyloid, AD= Alzheimer’s disease,  ATF-4 = Activating transcription 
factor 4, ATP= adenosine triphosphate, BACE1= β secretase,  BAX= Bcl2 associated X, Bcl = B-
cell lymphoma, BIO= 6-bromoindirubin-3′-oxime, BIP = binding immunoglobulin protein, BIX= 
BIP inducer X, CHOP= CCAAT enhancer binding protein homologous protein, eIF2α = 
eukaryotic initiation factor 2α kinase, ERSRE= endoplasmic reticulum stress response 
element, GADD34 = growth arrest and DNA damage inducible protein 34, GRP94 = glucose 
regulated protein 94 , GSK3β, Glycogen syntheses kinase 3β, HDAC = histone deacetylates, 
IRE-1 = inositol-requiring enzyme 1, ISRIB = integrated stress response inhibitor, JNK= Jun-N-
Kinase, NF-κB= Nuclear factor κB,  N.R. = not reported, PBA= 4-phenyl butyric acid, PERK = 
PRK-like ER kinase , RYR = ryanodine receptor, TDZD= thiadiazolidinone,  TUDCA = 
tauroursodeoxycholic acid, UPR= Unfolded Protein Response, XBP-1 = Xbox protein 1 and 
2DG = 2-deoxy-D-glucose. 
 
 
 
